Cefoselis (also known as FK 037 Sulfate) is a widely used beta-lactam antibiotic of the cephalosporin class. Cefoselis inhibits GABA-induced currents in a concentration-dependent manner with IC50 of 185 mM. Cefoselis possesses a superior antistaphylococcal activity on MSSA isolates to both other compounds being however equal active to Cefepime and Cefpirome on multiresistant enterobacteriaceae. Cefoselis is dose-dependently appeared in brain extracellular fluid in proportion to its blood level. Cefoselis, a new parenteral cephalosporin, is active against clinical isolates of both gram-positive and gram-negative aerobic bacteria.
Physicochemical Properties
Molecular Formula | C19H24N8O10S3 |
Molecular Weight | 620.64 |
Exact Mass | 620.077 |
Elemental Analysis | C, 36.77; H, 3.90; N, 18.05; O, 25.78; S, 15.50 |
CAS # | 122841-12-7 |
Related CAS # | Cefoselis;122841-10-5;Cefoselis hydrochloride;911212-25-4 |
PubChem CID | 9830519 |
Appearance | White to off-white solid powder |
LogP | 0.027 |
Hydrogen Bond Donor Count | 7 |
Hydrogen Bond Acceptor Count | 17 |
Rotatable Bond Count | 9 |
Heavy Atom Count | 40 |
Complexity | 1100 |
Defined Atom Stereocenter Count | 2 |
SMILES | S1C([H])([H])C(C([H])([H])N2C([H])=C([H])/C(=N\[H])/N2C([H])([H])C([H])([H])O[H])=C(C(=O)O[H])N2C([C@]([H])([C@@]12[H])N([H])C(/C(/C1=C([H])SC(N([H])[H])=N1)=N\OC([H])([H])[H])=O)=O.S(=O)(=O)(O[H])O[H] |
InChi Key | LZOLCSVRFKCSEM-ZQCAECPKSA-N |
InChi Code | InChI=1S/C19H22N8O6S2.H2O4S/c1-33-24-12(10-8-35-19(21)22-10)15(29)23-13-16(30)27-14(18(31)32)9(7-34-17(13)27)6-25-3-2-11(20)26(25)4-5-28;1-5(2,3)4/h2-3,8,13,17,20,28H,4-7H2,1H3,(H2,21,22)(H,23,29)(H,31,32);(H2,1,2,3,4)/b20-11?,24-12-;/t13-,17-;/m1./s1 |
Chemical Name | (6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((2-(2-hydroxyethyl)-3-imino-2,3-dihydro-1H-pyrazol-1-yl)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid compound with sulfuric acid (1:1) |
Synonyms | Cefoselis sulfate; Cefoselis (sulfate); FK 037; 6EY42207VS; Cefoselis sulfate (JAN); |
HS Tariff Code | 2934.99.9001 |
Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage.(2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
Targets | β-lactam | ||
ln Vitro | Cefoselis inhibits GABA-induced currents in a concentration-dependent manner with IC50 of 185 mM. Cefoselis possesses a superior antistaphylococcal activity on MSSA isolates to both other compounds being however equal active to Cefepime and Cefpirome on multiresistant enterobacteriaceae. Cefoselis is dose-dependently appeared in brain extracellular fluid in proportion to its blood level. Cefoselis, a new parenteral cephalosporin, is active against clinical isolates of both gram-positive and gram-negative aerobic bacteria. | ||
ln Vivo |
|
||
Animal Protocol |
|
||
References |
[1]. Cefoselis, a beta-lactam antibiotic, easily penetrates the blood-brain barrier and causes seizure independently by glutamate release. J Neural Transm (Vienna). 2004 Dec;111(12):1523-35. [2]. In vitro activities of cefoselis compared to β-lactams and other antibacterial agents aganst gram-positive and gram-negative clinical isolates. Chinese Journal of Infection and Chemotherapy, 2011. 4: p. 002. [3]. King, A., L. Bethune, and I. Phillips, The Comparative In Vitro Activity of FK-037 (Cefoselis), a New Broad-Spectrum Cephalosporin. Clin Microbiol Infect, 1995. 1(1): p. 13-17. |
||
Additional Infomation |
Cefoselis sulfate is an azaheterocycle sulfate salt. It is functionally related to a member of cefoselis. See also: Cefoselis (annotation moved to). |
Solubility Data
Solubility (In Vitro) |
Water : 5~14.29 mg/mL(~23.02 mM) DMSO : 3~100 mg/mL ( 4.83~161.12 mM ) |
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (4.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.5 mg/mL (4.03 mM) Solubility in Formulation 5: 25 mg/mL (40.28 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.6112 mL | 8.0562 mL | 16.1124 mL | |
5 mM | 0.3222 mL | 1.6112 mL | 3.2225 mL | |
10 mM | 0.1611 mL | 0.8056 mL | 1.6112 mL |